Novartis stock after-hours at EUR 128.09: minus 0.88 percent versus prior close
Published on 09/29/2026 at 20:30 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Novartis traded at EUR 128.09 after-hours at 8:20 p.m. CEST on September 29, 2026, down EUR 1.14, or 0.88 percent, versus the EUR 129.23 prior close at Lang & Schwarz.
Trading day in Germany
The euro quotation was below the previous Lang & Schwarz closing price during the after-hours phase following the Xetra session. The bid was EUR 127.42 and the ask was EUR 128.76.
Positive European regulatory opinion
On September 18, 2026, Novartis announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use adopted a positive opinion recommending marketing authorization for Cosentyx, or secukinumab, in adults with polymyalgia rheumatica who have an inadequate response to steroids or relapse during steroid tapering. The company said the European Commission was expected to issue a final decision within approximately two months. Novartis
Pelacarsen trial missed primary endpoint
In a September 4, 2026 announcement, Novartis said its Phase III Lp(a)HORIZON trial of pelacarsen did not meet its primary endpoint of reducing cardiovascular events compared with placebo. The trial evaluated 8,323 patients with elevated lipoprotein(a) and established cardiovascular disease. Novartis
